The FDA issued a CRL on these NDAs in Apr 2012, but stopped short of demanding a new trial (#msg-74854335). Alogliptin is a DPP-4 inhibitor, i.e. from the same class as MRK’s Januvia. Actos is a big-selling drug that Takeda has been marketing since the 1990s; it goes off-patent in the US in 2016.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.